A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

• Main Authors: Trudeau, M.E, Chapman, J.-A.W, Guo, B, Clemons, M.J, Dent, R.A, Jong, R.A, Kahn, H.J, Pritchard, K.I, Han, L, O’Brien, P, Shepherd, L.E, Parissenti, A.M
• 其他作者: DUKE-NUS MEDICAL SCHOOL
• 格式: Article
• 出版: 2020
• 在線閱讀: https://scholarbank.nus.edu.sg/handle/10635/183739

10.1186/s40064-015-1392-x